MedPath

Swiss Group for Clinical Cancer Research

🇨🇭Switzerland
Ownership
Private
Established
1965-01-01
Employees
-
Market Cap
-
Website
http://www.sakk.ch/

SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy

Phase 2
Terminated
Conditions
Prostate Cancer
Interventions
Radiation: Salvage Radiotherapy SRT
First Posted Date
2016-10-26
Last Posted Date
2022-04-14
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
112
Registration Number
NCT02945813
Locations
🇫🇷

Centre Hospitalier Régional Universitaire (CHRU) Jean Minjoz, Besançon, France

🇫🇷

Clinique Pasteur - Centre finistérien de radiothérapie et d'oncologie, Brest, France

🇫🇷

Centre de lutte contre le cancer Léon Bérard, Lyon, France

and more 24 locations

ODM-201 Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents.

Phase 2
Terminated
Conditions
Prostate Cancer Metastatic
Prostate Cancer
Interventions
Other: Placebo
First Posted Date
2016-10-14
Last Posted Date
2024-03-13
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
92
Registration Number
NCT02933801
Locations
🇫🇷

Institut Bergonié, Bordeaux, France

🇫🇷

Centre Oscar Lambret, Lille, France

🇫🇷

Centre de lutte contre le cancer Léon Bérard, Lyon, France

and more 29 locations

Neoadjuvant Treatment With Regorafenib and Capecitabine Combined With Radiotherapy in Locally Advanced Rectal Cancer

Phase 1
Terminated
Conditions
Rectal Cancer
Interventions
Radiation: Radiotherapy
Procedure: Surgery
First Posted Date
2016-09-22
Last Posted Date
2023-01-10
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
25
Registration Number
NCT02910843
Locations
🇨🇭

St. Claraspital Basel, Basel, Switzerland

🇨🇭

Universitätsspital Basel, Basel, Switzerland

🇨🇭

Inselspital Bern, Bern, Switzerland

and more 4 locations

Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Phase 1
Completed
Conditions
Follicular Lymphoma
Interventions
First Posted Date
2016-08-24
Last Posted Date
2022-06-10
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
25
Registration Number
NCT02877550
Locations
🇨🇭

Universitaetsspital Basel, Basel, Switzerland

🇨🇭

Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland

🇨🇭

Inselspital, Bern, Bern, Switzerland

and more 3 locations

Anti-EGFR-immunoliposomes Loaded With Doxorubicin in Patients With Advanced Triple Negative EGFR Positive Breast Cancer

Phase 2
Terminated
Conditions
Breast Cancer
Interventions
First Posted Date
2016-07-14
Last Posted Date
2021-09-29
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
48
Registration Number
NCT02833766
Locations
🇨🇭

Kantonsspital Aarau, Aarau, Switzerland

🇨🇭

Kantonsspital Baden, Baden, Switzerland

🇨🇭

Universitaetsspital-Basel, Basel, Switzerland

and more 12 locations

Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone

Phase 2
Terminated
Conditions
Cancer of the Prostate
Prostate Cancer
Interventions
First Posted Date
2015-12-29
Last Posted Date
2023-06-27
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
169
Registration Number
NCT02640534
Locations
🇨🇭

Kantonsspital Aarau, Aarau, Switzerland

🇨🇭

Universitaetsspital Basel, Basel, Switzerland

🇨🇭

Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, Switzerland

and more 12 locations

Physical Activity in Patients With Metastatic Colorectal Cancer Who Receive Palliative First-line Chemotherapy

Not Applicable
Terminated
Conditions
Metastatic Colorectal Cancer
Interventions
Other: standard therapy
Other: standard therapy + physical activity program
First Posted Date
2015-11-04
Last Posted Date
2022-11-07
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
100
Registration Number
NCT02597075
Locations
🇦🇹

Universitätsklinikum der PMU Salzburg, Salzburg, Austria

🇦🇹

Klinikum Wels-Grieskirchen GmbH, Wels, Austria

🇨🇭

Tumor Zentrum Aarau, Aarau, Switzerland

and more 21 locations

Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

Phase 2
Completed
Conditions
NSCLC Non-small Cell Lung Cancer
Interventions
Drug: MEDI4736 (anti-PD-L1)
First Posted Date
2015-10-09
Last Posted Date
2024-04-15
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
68
Registration Number
NCT02572843
Locations
🇨🇭

Stadtspital Triemli, Zürich, Zurich, Switzerland

🇨🇭

Kantonsspital Aarau, Aarau, Switzerland

🇨🇭

Kantonsspital Baden, Baden, Switzerland

and more 16 locations

Adjuvant Aspirin Treatment for Colon Cancer Patients

Phase 3
Terminated
Conditions
Colon Cancer
Interventions
Drug: Placebo
First Posted Date
2015-06-10
Last Posted Date
2025-05-16
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
1040
Registration Number
NCT02467582
Locations
🇨🇭

Kantonsspital Aarau, Aarau, Switzerland

🇨🇭

Spitalzentrum Biel, Biel, Switzerland

🇨🇭

Clinique de Genolier, Genolier, Switzerland

and more 57 locations

Rituximab With or Without Ibrutinib for Patients With Advanced Follicular Lymphoma

Phase 2
Terminated
Conditions
Follicular Lymphoma
Interventions
First Posted Date
2015-05-21
Last Posted Date
2024-03-13
Lead Sponsor
Swiss Group for Clinical Cancer Research
Target Recruit Count
190
Registration Number
NCT02451111
Locations
🇦🇹

Akademisches Lehrkrankenhaus Feldkirch, Feldkirch, Austria

🇩🇰

Aalborg Universitetshospital, Aalborg, Denmark

🇩🇰

Aarhus University Hospital, Aarhus, Denmark

and more 38 locations
© Copyright 2025. All Rights Reserved by MedPath